{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054454","form_type":"8-K","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.764600+00:00","generated_at":"2026-06-02T21:15:58.039608+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"STAAR Surgical Q1 net sales up 5% to $77.4M; net loss $0.07ps; raises FY24 EBITDA outlook","bullets":["Net sales $77.4M (+5% YoY; +7% constant currency); ICL sales +9% on +2% units.","Net loss $3.3M ($0.07 loss per share) vs net income $2.7M ($0.05) a year ago; Adjusted EBITDA $5.3M ($0.11) vs $10.0M ($0.20).","U.S. sales $5M, up 15% YoY and 21% sequentially; record cash $252.1M.","FY2024 net sales outlook reiterated at $335-$340M; Adjusted EBITDA guidance raised to ~$39M ($0.75 per share) from ~$36M.","APAC sales +9% (China +10%); EMEA +11%; largest-ever U.S. practice commitment to EVO ICL announced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054454","json":"https://secwatch.observer/filing/0000950170-24-054454.json","markdown":"https://secwatch.observer/filing/0000950170-24-054454.md","text":"https://secwatch.observer/filing/0000950170-24-054454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/0000950170-24-054454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/staa-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:15:58.039608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8da30ae9052c18ebdf81aa563cdba8b8ca0a9378","claim":"STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue $77.4 million, net income Net loss of $3.3 million or $0.07 loss per share, EPS $0.07 loss per share. Guidance reaffirmed.","evidence_excerpt":"(EVO ICLTM) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview • Net sales up 5% to $77.4 million and up 7% in constant currency • ICL sales up 9% and units up 2% • Gross margin at 78.9% vs. 78.3% year ago • Net loss of $3.3 million or $0.07 loss per share vs. net income of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/0000950170-24-054454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 29, 2024"},{"label":"Revenue","value":"$77.4 million"},{"label":"Net income","value":"Net loss of $3.3 million or $0.07 loss per share"},{"label":"EPS","value":"$0.07 loss per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}